EUCTR2005-002717-21-GB进行中（未招募）1 期
A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCER - n/a
Pfizer Inc,235 East 42nd Street, New York,NY 100170 个研究点目标入组 200 人开始时间: 2006年7月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Histologically confirmed adenocarcinoma of the prostate (a new diagnostic biopsy
- •is not required).
- •2.Evidence of metastatic disease either on bone or CT scans.
- •3.At least 18 years old.
- •4.PSA above 5 ng/mL.
- •5.Progressive disease after at least 1 hormonal treatment (orchiectomy, estrogens, LHRH therapy etc.) with documented testosterone levels less than 50 ng/dL (equivalent to 1.7 nmol/L) and progressive disease defined by the following:
- •- An increase in PSA>50% over nadir value on hormonal therapy measured on 3 successive occasions at least 1 week a part. If the third measurement is lower than the second, a fourth measurement will be taken. Only if the fourth measurement is higher than the second, the patient will be enrolled in the study.
- •- Disease progression as defined by RECIST
- •- Two or more new bone lesions
- •6.Concurrent use of LHRH agonist is required if the patient has not been surgically castrated.
- •7.Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 determined within 2 weeks prior to enrollment (Appendix E).
- •8.Recovered to CTCAE Grade 1 that are not considered a safety risk by the sponsor and investigator will be allowed.
- •9.Stable level of pain for at least one week before enrollment.
- •10.Absolute neutrophil count of >1.5 x 109/L and platelets >100 x 109/L.
- •11.Adequate blood chemistry parameters as defined by:
- •- Creatinine <1.7 mg/dL (equivalent to 151 micromol/L). If creatinine is >1.7 mg/dL, the calculated creatinine clearance must be >40 ml/min from the Cockcroft Gault or MDRD formulas (Appendix D).
- •- Bilirubin - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <1.5 x ULN
- •12. Hemoglobin >10 g/dL.
- •13. Written and voluntary informed consent understood, signed and dated.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Prior chemotherapy or radioisotopes treatment for prostate cancer.
- •2.Prior anti IGF 1R and antibody based investigational therapies. Other investigational therapies (targeted or vaccine), unless otherwise agreed by investigators and sponsor, will require 4 weeks wash out period before enrollment.
- •3.Antiandrogen therapy (eg, flutamide) for primary cancer within 4 weeks prior to enrollment (6 weeks in the case of bicalutamide, nilutamide or other long acting anti androgens).
- •4.Radiation therapy to more than 25% of the bone marrow.
- •5.Local radiation within 2 weeks of enrollment.
- •6.Surgery within 4 weeks prior to study enrollment or not fully recovered from side effects of previous procedures.
- •7.Use of products known to affect PSA levels within 4 weeks of enrollment (eg, PC Calm, PC Plus, PC SPES, finasteride).
- •8.A serious uncontrolled medical disorder or active infection that would impair the ability to receive study treatment.
- •9.Significant active cardiac disease including: uncontrolled high blood pressure (ie, systolic blood pressure >160 mmHg, diastolic blood pressure >95 mm Hg), unstable angina, deep venous thrombosis, pulmonary embolism, cerebro vascular attack, valvular disease, congestive heart failure, myocardial infarction within the previous 6 months, or serious cardiac arrhythmias.
- •10.Subjects who are receiving chronic high dose immunosuppressive steroid therapy. Use of high dose corticosteroids within 2 weeks prior to enrollment (=100 mg prednisone per day or >40 mg dexamethasone per day). Previous steroid treatment is allowed but must be stopped at enrollment. Low dose steroid use for the control of nausea and vomiting (eg, dexamethasone 20 mg/day for up to 5 days) will be allowed. Topical steroid use is permitted. Inhaled steroids are permitted. Use of dexamethasone as pre medication is not an exclusion criterion.
- •11.Known severe hypersensitivity reactions to docetaxel or other drugs formulated in polysorbate 80.
- •12.Medical contraindication to any of the docetaxel pre medications.
- •13.Neuropathy greater than Grade 1 or evidence of unstable neurological symptoms within 4 weeks prior to enrollment.
- •14. Brain metastasis. Unevaluated central nervous system (CNS) symptoms suggestive of brain metastases within 2 weeks prior to enrollment. CNS symptoms must be evaluated with a computerized tomography (CT) scan or magnetic resonance imaging (MRI).
- •15.Dementia or significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol.
- •16.Subjects with reproductive potential who are not using adequate barrier methods on treatment.
- •17.Active malignancy other than prostate cancer within the past five years with the exception of non melanoma skin cancer (basal or squamous-cell skin cancer).
- •18. Subjects who have been admitted to an institution by virtue of an order issued by either the judicial or administrative authorities.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 trial for patients with prostate cancer to receive study drugsof CP-751,871 in combination with Docetaxel/Prednisone orDocetaxel/Prednisone alone.Metastatic hormone refractory (androgen indepedent) progressive prostate cancer (HRPC)MedDRA version: 14.0Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-002717-21-DEPfizer Inc. 235 East 42nd Street, New York, NY 10017, USA200
进行中（未招募）
1 期
A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCEREstudio en fase 2, aleatorizado, no comparativo, abierto, multicéntrico, con dos grupos, de CP-751,871 en combinación con docetaxel/prednisona en pacientes con cáncer de próstata resistente a hormonas sin quimioterapia previa (Grupo A) o refractarios a docetaxel /prednisona (Grupo B)Metastatic hormone refractory(androgen independent) progressive prostate cancer (HRPC)Cáncer de próstata progresivo metastásico resistente a hormonas (CPRH) (independiente de andrógenos)EUCTR2005-002717-21-ESPfizer, S.A.120
进行中（未招募）
不适用
A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCEREUCTR2005-002717-21-NLPfizer Inc. 235 East 42nd Street, New York, NY 10017
招募中
不适用
PHASE 2 STUDY OF AGEN2034 AS MONOTHERAPY OR IN COMBINATION THERAPY WITH AGEN1884 IN SECOND-LINE CERVICAL CANCER-C53 Malignant neoplasm of cervix uteriMalignant neoplasm of cervix uteriC53PER-047-19Agenus Inc.,
未知
不适用
ot availablePER-010-10BRISTOL MYERS SQUIBB COMPANY,